Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pamiparib - BeiGene

Drug Profile

Pamiparib - BeiGene

Alternative Names: BeiGene-290; BGB-290; BGB-290-BeiGene; PARPi - BeiGene; PARTRUVIX

Latest Information Update: 28 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Developer BeiGene; Myriad Genetics
  • Class Antineoplastics; Aza compounds; Fluorinated hydrocarbons; Ketones; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Cancer
  • Phase II Gastric cancer; HER2 negative breast cancer
  • Phase I/II Glioblastoma; Glioma; Solid tumours
  • Suspended Prostate cancer

Most Recent Events

  • 28 Feb 2024 No recent reports of development identified for phase-0 development in Glioblastoma(Neoadjuvant therapy) in USA (PO, Capsule)
  • 08 Feb 2024 BeiGene in collaboration with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and National Cancer Institute completes a phase I/II clinical trials in Glioma (Second-line therapy or greater, Combination therapy) in USA (PO) (NCT03914742)
  • 04 Oct 2023 BeiGene in collaboration with Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and National Cancer Institute suspends phase I/II clinical trials in Glioma (Second-line therapy or greater, Combination therapy) in USA (PO), as NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer (NCT03914742)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top